Recruitment Status

Recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

22011

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Interventions: Etoposide, BCNU, AraC, Melphalan, Peripheral blood stem cell transplantation, G-CSF, Cyclophosphamide, Total Body Irradiation; Drug · Procedure · Biological + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma
Interventions: Anastrozole, Biospecimen Collection, Bone Scan, Chemotherapy, Computed Tomography, Exemestane, Letrozole, Oncotype DX Breast Cancer Assay, Positron Emission Tomography, Ribociclib Succinate; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1,978 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 244
States / cities: Jonesboro, Arkansas • Auburn, California • Berkeley, California + 201 more

Conditions: Solid Tumors
Interventions: DPTX3186; Drug
Lead sponsor: Dewpoint Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 8
States / cities: Los Angeles, California • Boulder, Colorado • New Haven, Connecticut + 5 more

Conditions: Autoimmune Diseases
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years to 115 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Autism Spectrum Disorder, Anxiety Disorders
Interventions: DINOSAUR, Psychoeducation; Behavioral · Other
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 4 Years to 6 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Irritability, Disruptive Mood Dysregulation Disorder, Oppositional Defiant Disorder, Attention Deficit Hyperactivity Disorder
Interventions: Psychotherapy; Behavioral
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 8 Years to 17 Years
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2037
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Suicide, Attempted, Suicide Ideation, Suicide, Suicide Prevention
Interventions: Stanley Brown Safety Planning Intervention and Follow-up Contacts (SPI+), Interpersonal Psychotherapy for Adolescents Ultra Short Crisis Intervention (IPT-A SCI); Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 12 Years to 24 Years
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: St. Petersburg, Florida • Baltimore, Maryland • New York, New York + 2 more

Conditions: Kidney Cancer, Urologic Malignant Disorders, Renal Cell Carcinoma, Familial Renal Cancer (FRC), Clear Cell Renal Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1990
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Childhood Cancer
Interventions: Family-Centered Communication Intervention; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 25 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
Interventions: Lepodisiran, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years to 80 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 17
States / cities: La Jolla, California • Northridge, California • Torrance, California + 14 more

Conditions: Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced Solid Tumor
Interventions: XTX501; Drug
Lead sponsor: Xilio Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Canton, Ohio • Fort Worth, Texas • Fairfax, Virginia

Conditions: Alcohol Use Disorder
Interventions: Evaluate the effects of Environmental Enrichment (EE) on alcohol consumption; Behavioral
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 21 Years to 100 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Recruiting clinical trials

Filter and sort this status page

Live official records

Auto Stem Cell Transplant for Lymphoma Patients

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

DPTX3186 in Wnt Pathway Activated Solid Tumors

Deciphering the Genetic Architecture of Autoimmune Diseases

DINO RCT - Treating Anxiety in Children With Autism

Psychotherapy for Irritability in Youth: Comparing Active Treatment to Nonactive Psychoeducation Supportive Psychotherapy

Preventing Suicidal Behavior With Diverse High-Risk Youth in Acute Care Settings

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders

COMUNICAR: Community-Led Family-Centered Communication for Cancer Survivorship Care

A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk

XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors

Environment and Alcohol: A Pilot Study